Circulating micrornas to predict the risk for metabolic diseases in the general population?

Diabetes

Volumn 66, Issue 3, 2017, Pages 565-567

  Dumas, Marc Emmanuel ^a   Emanueli, Costanza ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA 122; CIRCULATING MICRORNA; MICRORNA;

ANTIHYPERTENSIVE THERAPY; ARTICLE; EXOSOME; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK;

CIRCULATING MICRORNA; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME; MICRORNAS; RISK;

EID: 85019562909     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/dbi16-0072     Document Type: Article

References (19)

1. Alberti KGMM, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-A new worldwide definition. Lancet 2005;366: 1059-1062
2. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
3. ONeill S, Bohl M, Gregersen S, Hermansen K, ODriscoll L. Blood-based biomarkers for metabolic syndrome. Trends Endocrinol Metab 2016;27:363-374
4. Caporali A, Miscianinov V, Saif J, Emanueli C. MicroRNA transport in cardiovascular complication of diabetes. Biochim Biophys Acta 2016;1861(12 Pt B): 2111-2120
5. Rotllan N, Price N, Pati P, Goedeke L, Fernández-Hernando C. MicroRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 2016;246: 352-360
6. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012;93:583-593
7. Krötzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with antagomirs. Nature 2005;438:685-689
8. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98
9. Elmén J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-AntimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36:1153-1162
10. Elmén J, Lindow M, Schötz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899
11. Willeit P, Skroblin P, Moschen AR, et al. Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 2017;66:347-357
12. Kronenberg F, Kollerits B, Kiechl S, et al. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet 2014;7:822-829
13. Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010;12:19-30
14. Sever PS, Dahlöf B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001;19:1139-1147
15. Raitoharju E, Seppälä I, Lyytikäinen L-P, et al. Blood hsa-miR-122-5p and hsamiR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci Rep 2016;6:38262
16. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290-299
17. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol 2011;13:423-433
18. McCrae JC, Sharkey N, Webb DJ, Vliegenthart ADB, Dear JW. Ethanol consumption produces a small increase in circulating miR-122 in healthy individuals. Clin Toxicol (Phila) 2016;54:53-55
19. Lewis AP, Jopling CL. Regulation and biological function of the liver-specific miR-122. Biochem Soc Trans 2010;38:1553-1557